文献速递淋巴瘤白血病造血干细胞移植与细胞治疗

靶向CD24克服CD19 CAR-T耐药并诱导固有与适应性免疫

Combating CD24 to overcome CD19 CAR-T resistance via induction of innate and adaptive immunity in B-cell malignancies.
PubMed 文献 · Leukemia · 2026-10-12

研究开发CD24双特异性抗体和CXCR3武装CD24 CAR-T,在淋巴瘤和白血病模型中显示抗肿瘤活性,可克服抗原丢失和凋亡缺陷所致的CD19 CAR-T耐药;CD24靶向T细胞还能重编程巨噬细胞向M1样表型并增强吞噬清除;进一步构建分泌CD24 BiTE的双特异性CD19 CAR-T,同时靶向CD19和CD24以应对肿瘤异质性并取得更优疗效。

要点

  • CD24在侵袭性B细胞恶性肿瘤高表达,是克服CD19 CAR-T耐药的新免疫靶点。
  • CD24 BsAb和CD24 CAR-T在体外和体内克服抗原丢失及凋亡缺陷驱动的CD19 CAR-T耐药。
  • 分泌CD24 BiTE的双特异性CD19 CAR-T可同时靶向CD19和CD24,应对肿瘤异质性。

核心结论

  • CD24导向的过继T细胞疗法通过强烈诱导固有和适应性免疫,对B细胞恶性肿瘤具有应用价值。

研究设计与样本

  • 研究开发CD24×CD3双特异性抗体(CD24 BsAb)和CXCR3武装的CD24 CAR-T细胞,并在淋巴瘤和白血病模型中进行体外和体内评估。
  • 进一步工程化双特异性、双功能的CD19 CAR-T,使其分泌CD24双特异性T细胞衔接器(CD24 BiTE)。

主要发现

  • CD24 BsAb和CD24 CAR-T在体外和体内克服由抗原丢失和凋亡缺陷驱动的CD19 CAR-T耐药。
  • CD24靶向T细胞可将巨噬细胞重编程为M1样表型并增强吞噬清除。
  • 分泌CD24 BiTE的双特异性CD19 CAR-T同时靶向CD19和CD24,取得更优疗效。

临床怎么用

  • CD24导向的过继T细胞疗法可能用于B细胞恶性肿瘤,尤其是CD19 CAR-T耐药后。
  • 双靶向CD19和CD24的策略可能应对肿瘤抗原异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD24 is highly expressed in aggressive B-cell malignancies and represents a novel immunologic vulnerability to overcome resistance to CD19 chimeric antigen receptor T-cell (CAR-T) therapy. We developed a CD24 × CD3 bispecific antibody (CD24 BsAb) and CXCR3-armed CD24 CAR-T cells, both exhibiting potent antitumor activity in lymphoma and leukemia models. CD24 BsAb and CD24 CAR-T overcome CD19 CAR-T resistance driven by antigen loss and apoptosis defects in vitro and in vivo. Beyond direct cytotoxicity, CD24-targeted T cells reprogram macrophages toward an M1-like phenotype and enhance phagocytic clearance. We further engineered a dual-specific, dual-functional CD19 CAR-T that secretes a CD24 bispecific T-cell engager (CD24 BiTE), enabling simultaneous targeting of CD19 and CD24 to address tumor heterogeneity and achieve superior efficacy. Collectively, our study demonstrates that CD24-directed adoptive T-cell therapies are warranted for B-cell malignancies through robust induction of both innate and adaptive immune responses.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Yin Q, Gao J, Huang X, et al. Combating CD24 to overcome CD19 CAR-T resistance via induction of innate and adaptive immunity in B-cell malignancies. Leukemia. 2026. PMID: 42864416. doi:10.1038/s41375-026-03159-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。